Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring

CONCLUSIONS: BTK and pan-PI3K inhibition in mantle cell lymphoma demonstrates a promising efficacy signal. Addition of BCL2 inhibitors to a BTK and pan-PI3K combination remain suitable for further development in mantle cell lymphoma.PMID:34615723 | DOI:10.1158/1078-0432.CCR-21-2183

Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Caitlin M Stewart Laure Michaud Karissa Whiting Reiko Nakajima Chelsea Nichols Stephanie De Frank Paul A Hamlin Matthew J Matasar John F Gerecitano Pamela Drullinsky Audrey Hamilton David Straus Steven M Horwitz Anita Kumar Craig H Moskowitz Alison Moskow Source Type: research